Skip to main content
    S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    +0.01 (+0.71%)

    Market Cap: $14.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Seres Therapeutics Inc (MCRB) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Seres Therapeutics (MCRB) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Seres Therapeutics reported EPS of -$1.06, above the -$1.34 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(19/38)
    Avg Surprise
    +11.03%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.66
    Range-$1.53 - $0.28
    4 analysts
    Revenue Consensus
    $6.53M
    Range$303.80K - $13.13M
    4 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    MCRB has an expected report date of Mar 10, 2027.

    MCRB Earnings Call

    The latest MCRB earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, MCRB beat 19, missed 17 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $593000, up 68.9% from $351000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.06-$1.34-$1.34 - -$0.67+20.90%Beat-212.8%20 up, 1 downNov 4, 2026$593000
    Jun 30, 2026-$1.50-$2.07-$2.30 - -$2.07+27.54%BeatN/A20 up, 0 downAug 5, 2026$736000
    Mar 31, 2026-$2.08-$1.88-$1.88 - -$1.88-10.64%MissN/A10 up, 0 downMay 5, 2026$358000
    Dec 31, 2025-$1.76-$1.60-$1.60 - -$1.60-10.00%MissN/A10 up, 1 downMar 12, 2026$438000
    Sep 30, 2025$0.94$0.05N/AN/AN/AN/A11 up, 0 downNov 5, 2025$351000
    Jun 30, 2025-$2.27-$2.27-$2.60 - -$1.950.00%In lineN/A20 up, 1 downAug 6, 2025N/A
    Mar 31, 2025-$2.24$1.97-$2.40 - $5.60-213.71%MissN/A30 up, 0 downMay 7, 2025N/A
    Dec 31, 2024-$0.11-$0.20-$0.28 - -$0.13+44.81%BeatN/A3N/AMar 13, 2025$5.96M
    Sep 30, 2024-$6.60-$0.04N/AN/AN/AN/A50 up, 0 downNov 13, 2024N/A
    Jun 30, 2024-$4.40-$5.91-$6.40 - -$4.80+25.55%Beat-161.1%60 up, 1 downAug 13, 2024N/A
    Mar 31, 2024-$5.40-$7.25-$8.60 - -$5.20+25.52%BeatN/A60 up, 0 downMay 8, 2024N/A
    Dec 31, 2023-$0.32-$0.50-$1.00 - -$0.33+36.00%BeatN/A71 up, 0 downMar 5, 2024N/A
    Sep 30, 2023-$7.40-$10.65-$13.40 - -$7.60+30.52%BeatN/A70 up, 0 downNov 2, 2023N/A
    Jun 30, 2023$7.20$10.97$9.00 - $14.80-34.37%MissN/A71 up, 0 downAug 8, 2023$126.47M
    Mar 31, 2023-$11.40-$10.85-$12.80 - -$9.00-5.07%MissN/A80 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.54-$0.46-$0.55 - -$0.30-17.39%MissN/A80 up, 0 downMar 7, 2023N/A
    Sep 30, 2022-$9.80-$9.44-$11.00 - -$6.00-3.81%Miss-168.1%80 up, 0 downNov 2, 2022$3.44M
    Jun 30, 2022-$14.00-$12.30-$13.00 - -$9.20-13.82%MissN/A80 up, 0 downAug 3, 2022$1.22M
    Mar 31, 2022-$12.20-$10.04-$12.40 - -$7.20-21.51%MissN/A80 up, 0 downMay 4, 2022$1.49M
    Dec 31, 2021-$0.52-$0.44-$0.62 - -$0.03-18.18%MissN/A9N/AMar 1, 2022$7.22M
    Sep 30, 2021$14.40-$3.46N/A+516.18%BeatN/A7N/ANov 10, 2021$126.72M
    Jun 30, 2021-$10.60-$7.63-$8.80 - -$5.80-38.93%MissN/A9N/AAug 3, 2021$5.26M
    Mar 31, 2021-$7.80-$6.30-$7.60 - -$4.60-23.81%MissN/A6N/AMay 4, 2021$5.72M
    Dec 31, 2020-$0.23-$0.28-$0.34 - -$0.20+17.86%BeatN/A8N/AMar 2, 2021$17.56M
    Sep 30, 2020-$7.20-$5.00-$7.00 - -$4.00-44.00%MissN/A7N/ANov 9, 2020$1.42M
    Jun 30, 2020-$5.60-$5.16-$5.80 - -$4.40-8.53%MissN/A7N/AJul 28, 2020$6.04M
    Mar 31, 2020-$0.28-$0.28-$0.36 - -$0.240.00%In lineN/A5N/AMay 7, 2020$8.19M
    Dec 31, 2019-$5.00-$5.27-$7.80 - -$4.40+5.12%BeatN/A6N/AMar 2, 2020$7.62M
    Sep 30, 2019-$4.60-$5.27-$11.20 - -$4.20+12.71%BeatN/A7N/ANov 5, 2019$7.03M
    Jun 30, 2019-$4.80-$10.35-$12.80 - -$8.00+53.62%BeatN/A8N/AAug 6, 2019$12.53M
    Mar 31, 2019-$11.13-$9.20-$14.40 - $4.20-20.98%MissN/A7N/AMay 2, 2019$7.32M
    Dec 31, 2018-$0.52-$0.50-$0.78 - $0.24-4.00%MissN/A6N/AMar 6, 2019$10.63M
    Sep 30, 2018-$10.80-$10.92-$15.60 - -$4.60+1.10%BeatN/A7N/ANov 8, 2018$9.05M
    Jun 30, 2018-$13.60-$14.00-$15.80 - -$2.00+2.86%BeatN/A7N/AAug 2, 2018$4.61M
    Mar 31, 2018-$13.80-$15.25-$16.00 - -$14.40+9.51%BeatN/A6N/AMay 9, 2018$3.97M
    Dec 31, 2017-$0.72-$0.75-$0.81 - -$0.68+4.00%BeatN/A6N/AMar 8, 2018$3.06M
    Sep 30, 2017-$3.40-$9.90-$16.80 - -$4.00+65.66%BeatN/A9N/ANov 8, 2017$23.02M
    Jun 30, 2017-$13.80-$12.76-$15.60 - -$8.60-8.15%MissN/A6N/AAug 3, 2017$3.01M
    Mar 31, 2017-$12.60-$13.13N/A+4.04%BeatN/AN/AN/AMay 4, 2017$3.02M
    Dec 31, 2016-$0.63-$0.72N/A+12.50%BeatN/AN/AN/AMar 16, 2017$3.04M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.33, after -$16.51 the year before. It was -$33.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.33N/A
    Dec 31, 2024-$16.51N/A
    Dec 31, 2023-$11.92N/A
    Dec 31, 2022-$36.54N/A
    Dec 31, 2021-$4.52N/A
    Dec 31, 2020-$13.31N/A
    Dec 31, 2019-$25.53N/A
    Dec 31, 2018-$38.72N/A
    Dec 31, 2017-$30.52N/A
    Dec 31, 2016-$33.83N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2025Q3 for the period ended Sep 30, 2025, runs about 2,800 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20252,7798
    2025Q2Jun 30, 20252,6177
    2025Q1Mar 31, 20253,8999
    2024Q4Dec 31, 20245,97212
    2024Q3Sep 30, 20244,58110
    2024Q2Jun 30, 20244,81710

    2025Q3 Earnings Call

    Opening remarks

    Carlo Tanzi Investor Relations Thank you, and good morning. Today, before the market opened, we issued a press release with our third quarter 2025 financial results and business updates available on the Investors and News section of our website. We've also posted an updated corporate presentation. Before we begin, I'd like to remind everyone that we will be making forward-looking statements, including statements around the results of our current or planned clinical trials, studies and data readouts, our product candidates and their potential benefits, development plans and potential commercial opportunities, interactions with and feedback from the FDA, our ability to secure an R&D or other partnership and/or generate or obtain additional capital, financing or other resources, our planned strategic focus and operating plans, cost reduction actions and anticipated benefits and cash runway, the timing of any of the foregoing and other statements which are not historical facts. Actual results may differ materially due to various risks and uncertainties and other important factors described under Risk Factors in our recent SEC filings. We undertake no obligation to update these statements, except as required by law. On today's call with prepared remarks are Marella Thorell, our Co-Chief Executive Officer and Chief Financial Officer; and Dr. Matthew Henn, our Chief Scientific Officer. Additional members of the management team, including Tom DesRosier, Co-CEO and Chief Legal Officer; Terri Young, Chief Commercial and Strategy Officer; and Dr. Dennis Walling, SVP of Clinical Development, will be available during the Q&A portion of the call. And with that, I'll turn the call over to Marella.

    Marella Thorell Co-CEO and CFO Thank you, Carlo, and good morning, everyone. We made good progress during the quarter. Our immediate priority remains advancing SER-155, our lead investigational, oral, live biotherapeutic for the prevention of bloodstream infections, or BSIs, in adults undergoing allo-HSCT into a Phase II study. We believe that results in this study, if positive, could represent a very meaningful value creation event for the company. SER-155 represents a first-in-class mechanistically differentiated approach to address infections, including bloodstream and antimicrobial resistant infections, which are among the causes of mortality in medically compromised patients. In the Phase Ib study, treatment with SER-155 led to an impressive 77% relative risk reduction in bacterial bloodstream infections, along with decreased antibiotic exposure and febrile neutropenia. The therapy is designed to decolonize gastrointestinal pathogens, improve epithelial barrier integrity and restore immune balance, addressing root causes to prevent BSIs and therefore, reduce antibiotic use, antimicrobial resistance and often severe or fatal outcomes. Based on our analysis of the commercial opportunity, we believe that SER-155 could transform how allo-HSCT patients are managed and result in meaningfully improved patient outcomes.

    Frequently Asked Questions About MCRB

    When is Seres Therapeutics's next earnings date?

    Seres Therapeutics's next earnings report is expected for Mar 10, 2027.

    Did MCRB beat earnings estimates last quarter?

    Yes. Seres Therapeutics reported EPS of -$1.06 for the quarter ended Sep 30, 2026, above the -$1.34 estimate, a 20.90% surprise.

    What EPS do analysts expect from MCRB next quarter?

    The consensus EPS estimate for Seres Therapeutics for the quarter ending Dec 31, 2026 is -$0.66 from 4 analysts, with estimates from -$1.53 to $0.28.

    How often does MCRB beat earnings estimates?

    Seres Therapeutics beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -14.44%.